

# Dennis J Ahnen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8034791/publications.pdf>

Version: 2024-02-01

32  
papers

4,951  
citations

361045

20  
h-index

476904

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

6297  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Aspirin to Prevent Colorectal Adenomas. <i>New England Journal of Medicine</i> , 2003, 348, 891-899.	13.9	1,358
2	Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel. <i>American Journal of Gastroenterology</i> , 2012, 107, 1315-1329.	0.2	948
3	Folic Acid for the Prevention of Colorectal Adenomas. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2351.	3.8	818
4	The Increasing Incidence of Young-Onset Colorectal Cancer: A Call to Action. <i>Mayo Clinic Proceedings</i> , 2014, 89, 216-224.	1.4	349
5	Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 404-412.	1.1	341
6	A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. <i>New England Journal of Medicine</i> , 2015, 373, 1519-1530.	13.9	262
7	The Association of Lifestyle and Dietary Factors with the Risk for Serrated Polyps of the Colorectum. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2310-2317.	1.1	143
8	Association between Folate Levels and CpG Island Hypermethylation in Normal Colorectal Mucosa. <i>Cancer Prevention Research</i> , 2010, 3, 1552-1564.	0.7	110
9	Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 512-519.	1.1	71
10	Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 61.	3.8	68
11	Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. <i>Journal of Clinical Oncology</i> , 2017, 35, 2806-2813.	0.8	57
12	Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial. <i>Gut</i> , 2019, 68, 475-486.	6.1	51
13	Regional variability of colonocyte growth and differentiation in the rat. <i>The Anatomical Record</i> , 1992, 233, 409-414.	2.3	49
14	Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1229-1238.	1.1	44
15	Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives. <i>Gut</i> , 2015, 64, 101-110.	6.1	40
16	Risk factors for metachronous colorectal cancer following a primary colorectal cancer: A prospective cohort study. <i>International Journal of Cancer</i> , 2016, 139, 1081-1090.	2.3	32
17	Barriers to Lynch Syndrome Testing and Preoperative Result Availability in Earlyonset Colorectal Cancer: A National Physician Survey Study. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e185.	1.3	30
18	No Evidence for Posttreatment Effects of Vitamin D and Calcium Supplementation on Risk of Colorectal Adenomas in a Randomized Trial. <i>Cancer Prevention Research</i> , 2019, 12, 295-304.	0.7	28

#	ARTICLE	IF	CITATIONS
19	Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. <i>International Journal of Epidemiology</i> , 2016, 45, 940-953.	0.9	27
20	Ability of known susceptibility SNPs to predict colorectal cancer risk for persons with and without a family history. <i>Familial Cancer</i> , 2019, 18, 389-397.	0.9	23
21	Clinicopathologic Risk Factor Distributions for <i>MLH1</i> Promoter Region Methylation in CIMP-Positive Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 68-75.	1.1	21
22	Folic acid supplementation and risk of colorectal neoplasia during long-term follow-up of a randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 903-911.	2.2	18
23	<i>PIK3CA</i> Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1046-1051.	1.1	17
24	Risk factors for metachronous colorectal cancer or polyp: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 301-326.	1.4	13
25	Body mass index, calcium supplementation and risk of colorectal adenomas. <i>International Journal of Cancer</i> , 2019, 144, 448-458.	2.3	11
26	Family History of Colorectal Cancer Is Not Associated with Colorectal Cancer Survival Regardless of Microsatellite Instability Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1700-1704.	1.1	9
27	Improving on-time colorectal cancer screening through lead time messaging. <i>Cancer</i> , 2020, 126, 247-252.	2.0	9
28	CRC Screening, Past, Present, and Future: A Tribute to Emmet Keeffe. <i>Digestive Diseases and Sciences</i> , 2015, 60, 589-591.	1.1	3
29	Proliferation, apoptosis and their regulatory protein expression in colorectal adenomas and serrated lesions. <i>PLoS ONE</i> , 2021, 16, e0258878.	1.1	1
30	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1203.	2.4	0
31	Our New President—David A. Lieberman, MD, AGAF, FACG. <i>Gastroenterology</i> , 2018, 154, 1836-1842.e7.	0.6	0
32	Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1262-1265.	1.1	0